Schrodinger is expected to report a Q3 2026 loss of $0.65 per share on revenue of $47.64 million, with the current stock price of $27.14 trading slightly above the average analyst price target of $25.86.
Investors are primarily focused on the growth of software Annual Contract Value (ACV) as the company continues its strategic transition toward a hosted licensing model.
This shift aims to reach a 75% hosted revenue mix by 2028, though it has recently pressured software gross margins. Additionally, the market is monitoring updates on the newly launched Bunsen AI platform and clinical progress within the proprietary drug discovery pipeline.